Ironwood Pharmaceuticals, Inc. (FRA:I76)

Market Cap	490.22M +492.3%
Revenue (ttm)	313.54M +13.8%
Net Income	88.62M
EPS	0.54
Shares Out	n/a
PE Ratio	5.53
Forward PE	3.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.760
Previous Close	2.760
Day's Range	2.680 - 2.760
52-Week Range	0.478 - 4.480
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C ...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 100
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I76

Financial Performance

In 2025, Ironwood Pharmaceuticals's revenue was $296.15 million, a decrease of -15.72% compared to the previous year's $351.41 million. Earnings were $24.02 million, an increase of 2629.20%.

Financial numbers in USD